T-cell therapy for adults with relapsed or refractory B-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new T-cell therapy (EB103) for people with B-cell non-Hodgkin's lymphoma that has come back or stopped responding to treatment. It aims to see if the therapy is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a type of B-cell non-Hodgkin's lymphoma that has come back or not responded after at least two prior treatments (or one treatment for certain types).
- You must have had prior treatment that included an anti-CD20 antibody (like rituximab) and a chemotherapy drug called an anthracycline.
- Your cancer must show up on a PET scan.
- You must be generally well enough to be up and about at least half of the day (ECOG score 0–2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medicine called MBS303 to see how safe it is and how well it works in adults with B-cell non-Hodgkin lymphoma (NHL) that has come back or did not respond to prior anti-CD20 treatment. It may help people who have few or no treatment options expected to improve survival.
This trial tests a new kind of immune cell therapy for people with certain types of lymphoma that have come back or not responded to previous treatments. The cells are made from your own blood and are designed to find and attack the cancer cells.
This early trial tests a new type of cell therapy (called ARI0003) for aggressive B-cell lymphomas that have not responded to standard treatments or have relapsed. The therapy uses your own immune cells to fight the cancer, and it may offer a new option when other treatments have not worked well.
This early-phase study tests a lab-made immune cell treatment (cytotoxic T-lymphocytes) for certain lymphomas and related diseases that test positive for the Epstein-Barr virus (EBV). It may help your immune system attack EBV-infected cancer cells, especially after the cancer has come back or when transplant isn’t suitable.
This trial is testing a new treatment called CD19x22 CAR T cells for people with certain types of B-cell lymphoma that have come back or not responded to other treatments. The therapy uses your own immune cells, which are modified in a lab to better attack the cancer.
This trial tests a new immune cell treatment for adults with a type of blood cancer (B-cell lymphoma) that has come back or not improved after standard treatments. The therapy uses specially engineered immune cells to target and destroy cancer cells.
Hear when a new Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.